Lymphedema Clinical Trial
Official title:
Proof-of-concept Interventional Study to Evaluate the Feasibility of the New Method, LymphMonitor 1.0, to Assess Lymphatic Function, Consisting of Indocyanine Green-based Lymphatic Specific Tracer. and a Custom Fluorescence Measuring Investigational Device LymphMeter 1.0.
Verified date | July 2020 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Lymphedema is the consequence of injured lymphatic system and is characterized by chronic,
often disabling swelling of am affected body part, often arm or leg. In the western world
secondary lymphedema arises most commonly after removal lymph nodes in an operation as a part
of cancer treatment (for example from the armpits or the groin region), however it may also
develop as a result of radiation, any other operation, infection or injury that destroys a
part of lymphatic system. The disease often develops even years after the event. While there
is no cure for lymphedema at present, early detection would ensure timely physiotherapy and
application of compression garments that significantly slow down or stop the progression of
the disease. However, presently used methods of that are used for diagnosis and evaluating
the stage of the disease, are either invasive and expensive or inaccurate and can only be
performed at specialized medical centres.
Therefore, we developed a simple, affordable and accurate technology, LymphMonitor 1.0 that
can allow for testing how efficiently the lymphatic system is functioning. The test can be
performed at the local medical centre or potentially even at home.
In this study, we investigate whether LymphMonitor 1.0 technology can distinguish between a
healthy and a diseased lymphatic system (in lymphedema). This method may allow early
diagnosis of lymphedema so that the development of the disease can be detected and prevented
early enough. By participating in the study the lymphedema patients are making an important
contribution to increasing the quality of life of lymphedema patients. In LymphMonitor 1.0
method method, a solution of a safe fluorescent dye, indocyanine green, is injected
painlessly using tiny microneedles, MicronJet600TM, directly into the skin of the arm or leg.
After injection, this dye is removed from the skin only through the lymphatic vessels. The
intensity of the fluorescence signal corresponds to the amount of dye left in the skin. The
decrease in the fluorescence signal after the injection is measured on the surface on the
skin using a new device, LymphMeter 1.0. The faster the dye (and that fluorescence signal)
disappears from the surface of the skin, the better the lymphatic system works. Therefore in
the arm or leg affected by lymphedema the fluorescence signal will decrease much slower
compared to the healthy one.
Status | Completed |
Enrollment | 10 |
Est. completion date | June 26, 2020 |
Est. primary completion date | June 26, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion criteria: - informed consent as documented by signature - females and males 18 - 75 years old, - established (stage 2 or higher) unilateral secondary arm or leg lymphedema resulting from lymphadectonomy, radiation or any other surgical treatment, infection or injury. - good general health status. Exclusion criteria: - critical illness (active cancer, renal failure, hepatic dysfunction) - active infection - blood vascular malformations or diseases - scleroderma - primary lymphedema - patients who underwent any surgical procedures for treatment of lymphedema (e.g. lymphovenous anastomosis, liposuction, lymph node transfer). - contraindications to use ICG (VERDYE), i.e. - patients with hypersensitivity to ICG or to sodium iodide - patients with hypersensitivity to iodine, - patients with hyper-thyroidism, patients with autonomic thyroid adenomas - patients in which the injection of VERDYE was poorly tolerated in the past it must not be used again, since severe anaphylactic reactions might occur. - hypersensitivity to albumin or its excipients - women, who are pregnant (pregnancy test will be performed in case of women who did not undergo menopause), - women who are breast feeding , - enrolment of the investigator, his/her family members, employees and other dependent persons, - known or suspected non-compliance, drug or alcohol abuse, - inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, - participation in another study with investigational drug within the 30 days preceding and during the present study, - previous enrolment into the current study. |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hostpial Zurich | Zurich |
Lead Sponsor | Collaborator |
---|---|
Nicole Lindenblatt | Clinical Trials Center of the University Hospital Zurich, NanoPass Technologies Ltd, Swiss Federal Institute of Technology, Zurich University of Applied Sciences |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety outcomes | Specific safety outcomes in this study will consist of any signs of potential allergic reactions and irritation of injection sites or any other intolerances | 3 hours | |
Other | Safety outcomes | Any adverse effects (AEs) and serious adverse effects (SAEs) (expected and unexpected will be recorded | Through the study completion, an average of 5 hours | |
Primary | Areas under the normalized clearance curves (AUCs) | Areas under the normalized clearance curves (AUCs) in healthy and lymphedema limbs measured over 3 hours after injection. To obtain the clearance curve, the fluorescence intensity values at the injection sites in healthy and lymphedema extremities at pre-determined timepoints | Fluorescence values measured immediately after injection and 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours after injection. | |
Secondary | other clearance parameters: clearance constant (k) and half-life of clearance (t1/2); (healthy versus diseased). | Fluorescence values measured immediately after injection and 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours after injection. | ||
Secondary | Correlation/no correlation of clearance parameters with the extent of the swelling (limb volume) in lymphedema patients. | 3 hours | ||
Secondary | dimensions of the injected dye depot measured by FluoBeam | Images of the injection site over time will be recorded using Fluobeam at different and analysed. | Dimensions will be measured immediately after injection and 1.5 hours and 3 hours after injection. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05507346 -
A Clinical Study to Evaluate the Effectiveness of a Novel Portable Non-Pneumatic Active Compression Device vs. an Advanced Pneumatic Compression Device for Treating Lower Extremity Lymphedema
|
N/A | |
Completed |
NCT06067880 -
Surgical Intervention and Lymphatic Diseases.
|
||
Active, not recruiting |
NCT04797390 -
A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema
|
N/A | |
Completed |
NCT02676752 -
Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis
|
||
Completed |
NCT06323200 -
Lymphedema Duration on Lymphatic Vessel Quality and Outcomes After LVA
|
||
Completed |
NCT02506530 -
Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema
|
N/A | |
Terminated |
NCT02020837 -
A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema
|
Early Phase 1 | |
Completed |
NCT02253186 -
Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema
|
N/A | |
Recruiting |
NCT01318785 -
Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications
|
Phase 2 | |
Enrolling by invitation |
NCT02375165 -
Biomarkers for the Detection of Lymphatic Insufficiency
|
||
Completed |
NCT00852930 -
Low Level Laser Treatment and Breast Cancer Related Lymphedema
|
Phase 4 | |
Completed |
NCT01112189 -
Use of Stem Cells in Lymphedema Post Mastectomy
|
Phase 1/Phase 2 | |
Completed |
NCT02308488 -
Study of Prone Accelerated Breast And Nodal IMRT
|
N/A | |
Completed |
NCT00743314 -
Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer
|
Early Phase 1 | |
Recruiting |
NCT06237907 -
Pyroptosis and Ferroptosis in the Pathophysiology of Lymphedema
|
||
Terminated |
NCT01580800 -
National Breast Cancer and Lymphedema Registry
|
||
Suspended |
NCT05366699 -
LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy
|
N/A | |
Completed |
NCT06249360 -
Lymphatic System Reflux After Lymphatic Operation
|
||
Completed |
NCT06220903 -
The Effect of Complex Decongestive Therapy in Patients With Lymphedema
|
N/A | |
Terminated |
NCT02923037 -
Hatha Yoga in Breast Cancer Survivors
|
N/A |